Presentation
Investor Relations
Next Generation Insulin Delivery Technology
CEO Jeb Besser discusses the near-term milestones and catalysts for MODD's next-generation and disruptive insulin pump. This low-cost, simple-to-use insulin pump could be highly disruptive to incumbents as it could significantly increase the total addressable market for insulin pumps. FDA Submission occurred on Jan 19, 2024, with approval anticipated in the second half of 2024.
May 12, 2024
PropThink Diabetes Care Expert Call
KOLs discuss current landscape of insulin pump market and what must be done to take advantage of $3B opportunity